Details for New Drug Application (NDA): 217242
✉ Email this page to a colleague
The generic ingredient in ZORYVE is roflumilast. There are ten drug master file entries for this compound. Fourteen suppliers are listed for this compound. Additional details are available on the roflumilast profile page.
Summary for 217242
Tradename: | ZORYVE |
Applicant: | Arcutis |
Ingredient: | roflumilast |
Patents: | 13 |
Pharmacology for NDA: 217242
Mechanism of Action | Phosphodiesterase 4 Inhibitors |
Suppliers and Packaging for NDA: 217242
Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
---|---|---|---|---|---|---|---|---|
ZORYVE | roflumilast | FOAM;TOPICAL | 217242 | NDA | Arcutis Biotherapeutics, Inc. | 80610-430 | 80610-430-60 | 1 CAN in 1 CARTON (80610-430-60) / 60 g in 1 CAN |
Profile for product number 001
Active Rx/OTC/Discontinued: | RX | Dosage: | FOAM;TOPICAL | Strength | 0.3% | ||||
Approval Date: | Dec 15, 2023 | TE: | RLD: | Yes | |||||
Regulatory Exclusivity Expiration: | Dec 15, 2026 | ||||||||
Regulatory Exclusivity Use: | NEW PRODUCT | ||||||||
Patent: | ⤷ Subscribe | Patent Expiration: | Jun 7, 2037 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
Patent: | ⤷ Subscribe | Patent Expiration: | Aug 25, 2037 | Product Flag? | Substance Flag? | Delist Request? | |||
Patented Use: | TOPICAL TREATMENT OF SEBORRHEIC DERMATITIS IN PATIENTS 9 YEARS OF AGE AND OLDER |
Complete Access Available with Subscription